CUE Cue Biopharma, Inc.
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action c…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Cue Biopharma’s CUE-221 Hits Phase II Goals, Shows Durable CSU Response Cue Biopharma (NASDAQ:CUE) reported positive top-line results from a Phase II trial of CUE-221 in patients with moderate-to-severe chronic spontaneous urticaria, or CSU, whose disease was inadequately controlled with H1 antihistamines. The randomized, double-blind, placebo-controlled study evaluate | ||
 Cue Biopharma (CUE) Reports Hives Drug Results. Can Longer Relief Set it Apart? Cue Biopharma, Inc. (NASDAQ:CUE) reported positive Phase 2 results for CUE-221 on September 20. The randomized, double-blind study enrolled 145 patients in China with moderate to severe chronic spontaneous urticaria, or chronic hives, inadequately controlled by H1 antihistamines. At week 12, complete hive resolution occurred in 54% of patients receiving 4 mg/kg CUE-221 versus 11% […] | ||
 An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill. | ||
 Cue Biopharma Shares Jump 41.6% Premarket Following Phase 2 Trial Results Cue Biopharma (NASDAQ:CUE) shares rose 41. 6% in premarket trading after the company reported positive topline results from a Phase 2 clinical trial evaluating CUE-221 in patients with moderate to severe chronic spontaneous urticaria. | ||
 3 Small-Cap Biotech Stocks Pairing Rapid Revenue Growth With High Insider Ownership Most small-cap biotech stocks are pure clinical bets. These three already have revenue on the books and insiders backing them with their own capital. | ||